Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized IgG1 mAb against six-transmembrane epithelial antigen of the prostate 1 (STEAP1) protein and monomethyl auristatin E (MMAE)
Molecular Target
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today